Personalized pharmacotherapy for Type 2 diabetes mellitus

被引：9

作者：

Sathananthan, Airani ^{[1
]}

Vella, Adrian ^{[1
]}

机构：

[1] Mayo Clin, Div Endocrinol Diabet & Metab, Dept Med, Rochester, MN 55905 USA

来源：

PERSONALIZED MEDICINE | 2009年 / 6卷 / 04期

关键词：

OCT; 1; pharmacogenetics; sulfonylureas; TCF7L2; Type 2 diabetes mellitus; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; INSULIN-SECRETION; SECONDARY FAILURE; INCREASED RISK; TCF7L2; GENE; VARIANT; SULFONYLUREA; THERAPY; POLYMORPHISMS; PIOGLITAZONE;

D O I：

10.2217/PME.09.3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Genome-wide linkage and association studies have been applied to Type 2 diabetes in order to discover common genetic variation that contributes to disease risk. While there has been progress in understanding how genetic variation predisposes to diabetes, there is less of an understanding of how genetics can alter drug response. The hope is that in the future, pharmacogenetics can help guide the treatment of diabetes, thereby improving control while minimizing side effects in a large group of patients.

引用

页码：417 / 422

页数：6

共 50 条

[1] Pharmacotherapy of type 2 diabetes mellitus
Rendell, MS
Kirchain, WR
ANNALS OF PHARMACOTHERAPY, 2000, 34 (7-8) : 878 - 895
[2] Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy
Shlomai, Gadi
Neel, Brian
LeRoith, Derek
Gallagher, Emily Jane
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (35) : 4261 - +
[3] Pharmacogenetics and personalized treatment of type 2 diabetes mellitus
Yang, Pablo
Ojeda Heredia, Veronica
Beltramo, Dante M.
Soria, Nestor W.
INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2016, 36 (04) : 508 - 518
[4] Pharmacogenetics and personalized treatment of type 2 diabetes mellitus
Pablo Yang
Verónica Ojeda Heredia
Dante M. Beltramo
Néstor W. Soria
International Journal of Diabetes in Developing Countries, 2016, 36 : 508 - 518
[5] Proteomics for personalized medicine in type 2 diabetes mellitus
Wang, Mark
Gui, Yuan
Zhou, Dong
FASEB JOURNAL, 2021, 35
[6] Features of type 2 diabetes mellitus and its pharmacotherapy in outpatients
Samoilova, Iuliia G.
Podchinenova, Daria V.
Matveeva, Mariia V.
Oleynik, Oxana A.
Stankova, Anastasia E.
Kudlay, Dmitry A.
Mazurina, Anastasiia A.
Pak, Iuliia D.
Kharakhulah, Marina I.
TERAPEVTICHESKII ARKHIV, 2024, 96 (03) : 286 - 291
[7] Pharmacotherapy of type 2 diabetes mellitus in frail elderly patients
Sathyanarayanan, Abilash
Rabindranathnambi, Aswatha
Muraleedharan, Vakkat
BRITISH JOURNAL OF HOSPITAL MEDICINE, 2019, 80 (11) : C162 - C165
[8] Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus
Norris, SL
Zhang, X
Avenell, A
Gregg, E
Schmid, CH
Lau, J
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (01):
[9] Current trends in the pharmacotherapy of type 2 diabetes mellitus.
Kovelman, IR
Tochilkin, AI
Belayeva, NF
Gorodetskii, VK
Knyazhev, VA
Tkachenko, CB
Semenov, LL
Semenova, NV
VOPROSY MEDITSINSKOI KHIMII, 2002, 48 (04): : 337 - 352
[10] Pharmacotherapy of Type 2 Diabetes Mellitus: An Update on Drug–Drug Interactions
Muhammad Amin
Naeti Suksomboon
Drug Safety, 2014, 37 : 903 - 919

← 1 2 3 4 5 →